Literature DB >> 29134683

Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.

Jessica Slostad1, Patrick Hoversten1, Candace L Haddox1, Kamila Cisak2, Jonas Paludo2, Ayalew Tefferi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29134683     DOI： 10.1002/ajh.24971

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  16 in total

1.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

2.  Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis.

Authors:  Romain Lévy; Mathieu Fusaro; Frédéric Guerin; Ahmed Chetouani; Despina Moshous; Alain Fischer; Geneviève de Saint Basile; Fernando E Sepulveda; Bénédicte Neven
Journal:  Blood Adv       Date:  2020-04-14

3.  Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Scott R Goldsmith; Sana Saif Ur Rehman; Cara L Shirai; Kiran Vij; John F DiPersio
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

5.  Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Sabrin Albeituni; Katherine C Verbist; Paige E Tedrick; Heather Tillman; Jennifer Picarsic; Rachel Bassett; Kim E Nichols
Journal:  Blood       Date:  2019-04-23       Impact factor: 22.113

6.  Treosulfan-Based Conditioning in Matched Family, Unrelated and Haploidentical Hematopoietic Stem Cell Transplantation for Genetic Hemophagocytic Lymphohistiocytosis: Experience and Outcomes over 10 Years from India.

Authors:  Venkateswaran Vellaichamy Swaminathan; Ramya Uppuluri; Satish Kumar Meena; Harika Varla; Rumesh Chandar; Balasubramaniam Ramakrishnan; Indira Jayakumar; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2021-03-06       Impact factor: 0.900

Review 7.  Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis.

Authors:  Mounica Vallurupalli; Nancy Berliner
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

8.  Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Authors:  Ayalew Tefferi; Daniela Barraco; Terra L Lasho; Sahrish Shah; Kebede H Begna; Aref Al-Kali; William J Hogan; Mark R Litzow; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Blood Cancer J       Date:  2018-03-07       Impact factor: 11.037

Review 9.  Cell Versus Cytokine - Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity.

Authors:  Oliver Wegehaupt; Katharina Wustrau; Kai Lehmberg; Stephan Ehl
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

10.  A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.

Authors:  Qing Zhang; Ang Wei; Hong-Hao Ma; Li Zhang; Hong-Yun Lian; Dong Wang; Yun-Ze Zhao; Lei Cui; Wei-Jing Li; Ying Yang; Tian-You Wang; Zhi-Gang Li; Rui Zhang
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.